Cycle Pharma

Cambridge, United Kingdom Founded: 2012 • Age: 14 yrs
Small molecule drugs are reformulated and repurposed for orphan indications.
Annual revenue $30.2M Latest available
Total funding - 1 rounds
Employees 54 Tracked headcount
Investors 1 Known backers
Products 2 Services tracked
Competitors 10 Brand Intelligence

About Cycle Pharma

Cycle Pharma is a company based in Cambridge (United Kingdom) founded in 2012. The company has 54 employees as of December 31, 2021. Cycle Pharma has completed 2 acquisitions, including Applied Therapeutics and Banner Life Sciences. Cycle Pharma offers products and services including Cycle Vita and VENXXIVA. Cycle Pharma operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Alnylam, among others.

  • Headquarter Cambridge, United Kingdom
  • Employees 54 as on 31 Dec, 2021
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Cycle Pharmaceuticals Ltd
  • Date of Incorporation 02 Feb, 2012
  • Jurisdiction CAMBRIDGE, ENGLAND
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $30.23 M (USD)
    31
    as on Dec 31, 2020
  • Net Profit
    $10.71 M (USD)
    67
    as on Dec 31, 2020
  • EBITDA
    Not available
  • Latest Funding Round
    $25 M (USD), Debt – Conventional

    Sep 07, 2020

  • Investors
  • Employee Count
    54

    as on Dec 31, 2021

  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Cycle Pharma

Cycle Pharma offers a comprehensive portfolio of products and services, including Cycle Vita and VENXXIVA.

Product name locked
Category locked
Primary

AI-powered app for managing rare diseases like PKU.

Product name locked
Category locked
Locked

Tablets for treating cystinuria and reducing pill burden.

People of Cycle Pharma

Headcount 10-50
Employee Profiles 29
Board Members and Advisors 6
Employee Profiles
People
David R.
Director Of Sales, Hematology & Oncology
People
Damien Sango
Director, Market Access And Distribution
People
Zac Bohlen
VP, US Sales
People
Catherine Wainwright
Senior Director of New Product Introduction & Programme Management

Unlock access to complete

Board Members and Advisors
people
Tony Cates
Director
people
Bill Robinson
Deputy Chairman
people
Duncan Moore
Director
people
Ross Reason
Director

Unlock access to complete

Funding Insights of Cycle Pharma

Investors in Cycle Pharma

Cycle Pharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Deutsche Bank.

All
Institutional
Investor Description Founded Year Domain Location
Diversified banking and financial services are provided globally.
Locked Locked Locked
Premium access

Investor details for Cycle Pharma

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Cycle Pharma

Cycle Pharma has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Applied Therapeutics and Banner Life Sciences.

Investments
Premium access

Investment portfolio details for Cycle Pharma

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Drugs for metabolic and cardiovascular diseases are developed.
Locked Locked 2015 Locked
Fully integrated product development using its formulation technologies.
Locked Locked 1994 Locked
Premium access

Complete acquisition details for Cycle Pharma

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Cycle Pharma

Premium access

Detailed financials for Cycle Pharma

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Cycle Pharma Comparisons

Cycle Pharma Primary company
Description
Small molecule drugs are reformulated and repurposed for orp...
Location
Cambridge, United Kingdom
Founded Year
2012
Annual Revenue
$30.23 M (USD)
Net Profit
$10.71 M (USD)
EBITDA
Not available
Employees
54
As of 2021
Premium access

Peer comparison for Cycle Pharma

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Cycle Pharma

Cycle Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Alnylam, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
mRNA-based therapeutics for diseases including cancer and infections are developed.
Locked Locked Locked
Novel biopharmaceutical medicines are developed for unmet medical needs.
Locked Locked Locked
Targeted and immune-oncology drugs for cancer treatment are developed.
Locked Locked Locked
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
Locked Locked Locked
RNA interference-based therapeutics are developed for multiple disorders.
Locked Locked Locked
Small molecules are developed for cancer and skin disease treatments.
Premium access

Detailed competitors of Cycle Pharma

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Cycle Pharma

Premium access

Complete news archive for Cycle Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Cycle Pharma

Cycle Pharma was founded in 2012 and raised its 1st funding round 8 years after it was founded.

Cycle Pharma is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.

As of Dec 31, 2021, the latest employee count at Cycle Pharma is 54.

Annual revenue of Cycle Pharma is $30.23M as on Dec 31, 2020.

Cycle Pharma was founded in 2012 and is based in Cambridge, United Kingdom. Operations focus on biopharmaceutical development, including reformulation and repurposing of small molecule drugs for orphan diseases. FDA approval was granted in August 2017 for NITYR (nitisinone tablets), used to treat Hereditary Tyrosinemia type 1, with a formulation that avoids refrigeration and allows dissolution in water for pediatric use. Generics are also manufactured by the company.

Cycle Pharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.

Cycle Pharma offers Cycle Vita and VENXXIVA.

Cycle Pharma has made 2 acquisitions, including Applied Therapeutics, and Banner Life Sciences.

Cycle Pharma has 1 investor. Key investors include Deutsche Bank.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available